The total cellular AM2 level is a poorer predictor of survival in this disease (patients with pancreatic cancer and a high expression of AM2 showed a median survival of 10 months shorter than the remainder of the cohort studied). The gene discussed is ADM2; the disease is familial pancreatic carcinoma.